Pieter Van Vlierberghe retweeted
Our Erasmus Virtual Hematology Lectures will continue on September 19 at 16.00 CET (every two weeks) with a fantastic line up.
us06web.zoom.us/j/8963513079…
ID: 896 3513 0792
We will start with Omar Abdel Wahab from MSKCC.
Spread the news 📯📯
@AbdelWahablab @intercept_mds
Pieter Van Vlierberghe retweeted
By unlocking the untapped potential of existing medicines in new areas, the #REMEDI4ALL consortium will contribute, together with renowned international collaborators, to address unmet medical needs.
➡️ Find out more here: remedi4all.org/ #R4ALL #MedicinesRepurposing
Pieter Van Vlierberghe retweeted
The Anticancer Fund is very enthusiastic about this ambitious initiative in #drugrepurposing, or finding new therapeutic options for existing drugs. We have been a leader in this field to find new #cancer treatments and will now join efforts with 24 organisations! #anticancerfund
REMEDi4ALL is a #HorizonEU research initiative to drive forward the repurposing of medicines in Europe. The project, involving 24 organisations, has the potential to reduce times & costs of drug development.
👉 More here: remedi4all.org/
#R4ALL #MedicinesRepurposing
Pieter Van Vlierberghe retweeted
My first postdoc paper is now online 🥳
EZH2 cooperates with MYCN in driving T cell lymphoma - as a transcriptional activator, independent of its role as a repressor in the PRC2 complex!
👇doi.org/10.1182/blood.202201… 👇
@vib_ccb @Onco_KULeuven @VIBLifeSciences @BloodJournal
Pieter Van Vlierberghe retweeted
Help shine a light on #GBMDay by sharing one or more of these quick, impactful stats about glioblastoma and inspire others to take action. Your voice will help highlight the need to ensure better treatments, a better quality of life, and cures for GBM patients and caregivers.
Pieter Van Vlierberghe retweeted
Excited to share our latest publication
"RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition", opening perspectives for new therapeutic approaches for high-risk neuroblastoma patients.
science.org/doi/10.1126/scia…
Pieter Van Vlierberghe retweeted
Today is Glioblastoma Awareness Day and @KaziaTx has joined @NBTStweets to shine a light on the disease! GBM is the most treatment-resistant and deadliest brain cancer. For more info on #GBMDay and an update on $KZIA's potential #treatment, visit https://nitter.cf/t.co/tufioQcyzk
Pieter Van Vlierberghe retweeted
Splicing dysregulation in human hematologic malignancies: beyond splicing mutations dlvr.it/STz3Bw #immunology
Pieter Van Vlierberghe retweeted
Read our review on how, other than via coding sequence mutations, splicing aberrations can cause blood cancers. We review how the scientific community targets these mechanisms for new generation of therapeutics.
Splicing dysregulation in human hematologic malignancies: beyond splicing mutations dlvr.it/STz3Bw #immunology
Pieter Van Vlierberghe retweeted
Tomorrow is #GBMDay. We will not stop until we conquer and cure glioblastoma (#GBM) — once and for all. Take action now: braintumor.org/take-action/g…
Visiting Antwerp with my great friend and mentor @adolfo_ferrando 👍 Thanks so much for taking the time to stop ☺️ it was amazing 🤩
34
Pieter Van Vlierberghe retweeted
Spread the word: still 2 weeks to apply for an interesting post-doc (bioIT) position in our TOBI team #ERC_COG @ugent_fge @crighent
career012.successfactors.eu/…
Pieter Van Vlierberghe retweeted
Excited to share our latest publication "RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition" science.org/doi/10.1126/scia… @crighent
Pieter Van Vlierberghe retweeted
PU.1-dependent enhancer inhibition separates Tet2-deficient #hematopoiesis from malignant transformation, by @aivaliotim et al.
https://nitter.cf/t.co/ILEuektiGl
@EinsteinMed
Pieter Van Vlierberghe retweeted
MEF2C opposes Notch in lymphoid lineage decision and drives leukemia in the thymus: buff.ly/3NZX9Dk
@JulesMeijerink @prinsesmaximac
#Hematology #Oncology
Pieter Van Vlierberghe retweeted
Recent grant funding successes 🎉 = time for recruiting. Join our team! For those considering postdoctoral training and interested in the biology of aging, please get in touch!
This quoted post is unavailable.
Pieter Van Vlierberghe retweeted
🤩Online today @ScienceAdvances our new study on the role of ASNS in cancer and why it cannot predict response to L-asparaginase thanks to @ChicheJohanna @MGrimaReyes and to @laliguecancer @meta_canproject for their support! science.org/doi/10.1126/scia…
Pieter Van Vlierberghe retweeted
Finally first research paper on #Multiomics on T-ALL biology supported and funded from the #H2020 #Twinning @nextlevelEU project! It's #openaccess so you are invited to read! pubmed.ncbi.nlm.nih.gov/3577…
@ugent @crighent @researchumcg @uni_ulm


































